TREMELIMUMAB\TREMELIMUMAB-ACTL: 1,173 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
1,173
Total FAERS Reports
328 (28.0%)
Deaths Reported
428
Hospitalizations
1,173
As Primary/Secondary Suspect
165
Life-Threatening
17
Disabilities
First Report: 20230101 · Latest Report: 20250917
What Are the Most Common TREMELIMUMAB\TREMELIMUMAB-ACTL Side Effects?
#1 Most Reported
Diarrhoea
109 reports (9.3%)
#2 Most Reported
Death
106 reports (9.0%)
#3 Most Reported
Malignant neoplasm progression
101 reports (8.6%)
All TREMELIMUMAB\TREMELIMUMAB-ACTL Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Diarrhoea | 109 | 9.3% | 26 | 63 |
| Death | 106 | 9.0% | 106 | 4 |
| Malignant neoplasm progression | 101 | 8.6% | 38 | 12 |
| Cytokine release syndrome | 86 | 7.3% | 14 | 34 |
| Immune-mediated enterocolitis | 63 | 5.4% | 18 | 40 |
| Liver disorder | 62 | 5.3% | 8 | 19 |
| Pyrexia | 61 | 5.2% | 11 | 28 |
| Rash | 60 | 5.1% | 4 | 24 |
| Colitis | 47 | 4.0% | 12 | 24 |
| Immune-mediated hepatic disorder | 45 | 3.8% | 6 | 19 |
| Interstitial lung disease | 41 | 3.5% | 20 | 23 |
| Hepatic function abnormal | 39 | 3.3% | 6 | 18 |
| Adrenal insufficiency | 30 | 2.6% | 5 | 11 |
| Myocarditis | 29 | 2.5% | 14 | 17 |
| Malaise | 28 | 2.4% | 6 | 11 |
| Neutrophil count decreased | 26 | 2.2% | 8 | 11 |
| Platelet count decreased | 26 | 2.2% | 3 | 13 |
| Decreased appetite | 25 | 2.1% | 11 | 8 |
| Acute kidney injury | 22 | 1.9% | 7 | 15 |
| Enterocolitis | 22 | 1.9% | 4 | 9 |
Who Reports TREMELIMUMAB\TREMELIMUMAB-ACTL Side Effects? Age & Gender Data
Gender: 18.5% female, 81.5% male. Average age: 71.1 years. Most reports from: JP. View detailed demographics →
Is TREMELIMUMAB\TREMELIMUMAB-ACTL Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2023 | 308 | 87 | 175 |
| 2024 | 168 | 50 | 88 |
| 2025 | 77 | 24 | 33 |
What Is TREMELIMUMAB\TREMELIMUMAB-ACTL Used For?
| Indication | Reports |
|---|---|
| Hepatocellular carcinoma | 589 |
| Non-small cell lung cancer | 343 |
| Hepatic cancer | 12 |
| Lung neoplasm malignant | 12 |
| Non-small cell lung cancer stage iv | 9 |
| Product used for unknown indication | 5 |
TREMELIMUMAB\TREMELIMUMAB-ACTL vs Alternatives: Which Is Safer?
TREMELIMUMAB\TREMELIMUMAB-ACTL vs TRENBOLONE
TREMELIMUMAB\TREMELIMUMAB-ACTL vs TREOSULFAN
TREMELIMUMAB\TREMELIMUMAB-ACTL vs TREPROSTINIL
TREMELIMUMAB\TREMELIMUMAB-ACTL vs TREPROSTINIL DIOLAMINE
TREMELIMUMAB\TREMELIMUMAB-ACTL vs TRETINOIN
TREMELIMUMAB\TREMELIMUMAB-ACTL vs TRIAMCINOLONE
TREMELIMUMAB\TREMELIMUMAB-ACTL vs TRIAMCINOLONE ACETONIDE
TREMELIMUMAB\TREMELIMUMAB-ACTL vs TRIAMCINOLONE HEXACETONIDE
TREMELIMUMAB\TREMELIMUMAB-ACTL vs TRIAMTERENE
TREMELIMUMAB\TREMELIMUMAB-ACTL vs TRIATEC
Official FDA Label for TREMELIMUMAB\TREMELIMUMAB-ACTL
Official prescribing information from the FDA-approved drug label.